Sickle Cell Research: What’s Next? #ASH19 #ASH @LevineCancer
Ifeyinwa (Ify) Osunkwo, MD of @LevineCancer discusses the unmet needs in sickle cell research.
Related Articles
HCC Treatment Selection: 2025 ASCO Video Guide
Explore HCC treatment selection with guidelines from ASCO 2025 to improve patient outcomes and management of hepatocellular carcinoma.
FDA Approves Taletrectinib for ROS1-Positive NSCLC – Full Details
FDA approves taletrectinib for ROS1-positive NSCLC on June 11, 2025. Learn about trial results, dosage, and side effects in this easy guide.
ASCO 2025: Cancer Research on Lymphopenia & Immunity
Explore ASCO 2025 cancer research on treatment-induced lymphopenia and immune health. Insights for oncologists from Ohio State and Dana-Farber.
Digestive Cancers Therapeutics: Advances in Trials and Treatments
Delve into Digestive Cancers Therapeutics and learn about effective treatments and global health challenges in cancer care.
Darolutamide FDA Approval 2025: Prostate Cancer mCSPC Data
Discover the significance of the Darolutamide FDA Approval 2025 and how it advances prostate cancer care for patients.
Tarlatamab Phase 3 Results: New SCLC Standard at ASCO 2025
Tarlatamab Phase 3 Results: New SCLC Standard at ASCO 2025Explore the DeLLphi-304 study at ASCO 2025: tarlatamab offers 13.6 months median survival vs 8.3 months…
Pancreatic Cancer Treatment Updates from ASCO 2025: Key Insights for Oncologists
Discover the latest pancreatic cancer treatment standards from ASCO 2025, including FOLFIRINOX outcomes for PDAC. Watch the video on OncologyTube.com for expert insights.
ASCO25 Results: IO-Based Combinations in mRCC Survival Data
Dr. Brian Rini shared crucial results on IO-based combinations in mRCC at ASCO 2025. Find out how they improve outcomes.
Neoadjuvant Nivolumab Plus Chemotherapy in Lung Cancer: CheckMate 816 Update at ASCO 2025
Watch a brief video summarizing the benefits of Neoadjuvant Nivolumab Plus Chemotherapy CheckMate 816 for NSCLC patients.
Timing of Immunotherapy NSCLC: Survival Gains at ASCO 2025
The timing of immunotherapy NSCLC can be pivotal. Find out how infusion timing affects survival and treatment efficacy.